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Three classes o f  hum an  leucocyte FC7  receptors (I1FC7 R) have been identified so far: I1 FC7 R I, hFc7 R II, 
and I1FC7 RIIL Previous studies have dem onstrated  th a t  genetically determ ined differences between 
individuals exist bo th  with respect to the binding o f m urine Ig G l (m lg G l)  to h F c 7  receptors, and  w ith 
respect to the binding o f m urine IgG2b (mIgG2b). The polym orphism  in binding o f  m lg G l could be 
ascribed to I1FC7 R IIA , an isoform o f UFbyRIL The authors have now investigated w hether one o f  the 
isoforms of I1 FC7 R II is also responsible for the polym orphism  in binding o f  m IgG 2b. In  these studies the 
authors used EBV -transform ed hum an  B cells th a t  dem onstra ted  either b inding o r no binding of 
m IgG 2b in EA-rosetting assays. m R N A  obtained from  these cells was amplified by reverse transcrip tase 
and polymerase chain reaction (R T-PC R). H ybridization experiments w ith the R T -P C R  products 
revealed that the h F c7 RIIB  bu t n o t the hFc7 R IIA  isoform  was present in these cells. D N A  sequencing 
further dem onstrated that the nucleotide sequence of bo th  the extracellular p a r t  an d  the cytoplasm ic 
moiety of I1FC7 RIIB  was identical for all individuals tested, regardless o f  their ability to b ind  m IgG 2b. 
These findings indicate tha t the polym orphic binding o f  m IgG 2b  canno t be ascribed to one o f  the 
isoforms of I1FC7 RIL Since I1 FC7 R I and h F c7 R III are no t present on the cell surface o f these cells, the 
authors conclude th a t an Fc receptor different from  the know n I1 FC7  receptors m ust be responsible for 
the polymorphic binding of m IgG 2b. These data  further expand the com plexity o f I1 FC7 R.
W. J. M . T ax , D epartm ent o f  M edicine, Division o f  Nephrology, University H osp ita l N ijm egen , PO  B o x  
9101 , 6500 H B  N ijm egen , the Netherlands
IN T R O D U C T IO N
W hen murine monoclonal antibodies (MoAb) are used for 
immunotherapy, their biological effects and clinical side- 
effects are strongly influenced by their interaction (or lack 
o f  it) with human FC7  receptors (hFc7 R). This has been 
demonstrated both in tumour therapy [1 , 2] and in immuno­
suppressive therapy after organ transplantation [3, 4]. Three 
classes o f human leucocyte FC7 R  have been identified at the 
molecular level: hFc7 RI, hFc7RII, and hFc7 RIII [5, 6]. 
M urine IgG2a can bind to I1FC7 RI. m lgG l can bind to an 
isoform of I1FC7 RII, but this binding is polymorphic: 70% of 
Caucasians are m lgG l ‘high-responder5 (HR) whereas 30% 
are m lgG l low-responder (LR) [7, 8].
We have described a similar polymorphism with respect to 
the binding of mIgG2b to hum an mononuclear cells. T  cell 
proliferation was induced by mIgG2b anti-C D 3 M oAb only 
when accessory cells were present that could bind mIgG2b. In 
this way m IgG 2b-H R and m IgG2b-LR individuals could be 
defined [9], The percentage of m IgG 2b-H R  is much lower 
(3%) than the percentage o f m lg G l-H R  (70%)* It is im por­
tant to note that mIgG2b anti-C D 3 M oA b (in contrast to 
m lgG l) was still mitogenic after the complete removal of 
monocytes from the mononuclear cells o f m IgG2b-HR indi­
viduals [9], indicating that other cells than monocytes (pre­
sumably B cells) can also provide accessory function. The 
mIgG2b polymorphism could also be demonstrated in EBV- 
transformed B cells [9-11]. The I1FC7 R responsible for the
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polymorphic binding of mIgG2b has not yet been identified. 
Since I1FC7 RI and hFc7 RIII are not present on EBV-trans- 
formed B cells that can bind mIgG2b [9], hFc7 RII appeared 
to be the most likely candidate, as was also suggested by 
studies with polymeric mIgG2b [12].
I1FC7RII occurs in several isoforms, tha t are encoded by 
three genes: hFc7 RIIA, I1FC7 RIIB, and I1FC7 RIIC. The 
transcripts from I1FC7 RIIA (hFc7 RIIa) and I1FC7RIIB 
(hFc7RIIb) are highly homologous in the extracellular and 
transmembrane regions, but differ in the cytoplasmic region 
[13]. The transcript of FC7 RIIC (hFc7 RIIc) is identical to 
hFc7RIIb in its extracellular and transmembrane region, 
whereas in the cytoplasmic region it is identical (except for 
a single amino acid) to hFc7 R IIa [14]. Three different iso­
forms of hFc7 RIIb have been described, that result from 
alternative splicing. hFc7 R IIb2 and hFc7 R IIb 3 differ only in 
the signal sequence, whereas hFc7 R IIb l differs from 
hFc7 RIIb2 by a 19-amino acid insertion in the cytoplasmic 
tail [13]. hFc7 R IIa occurs in two allelic forms, and is respon­
sible for the polymorphism in binding o f m lg G l to human 
monocytes [5, 6],
We have now employed EBV-transformed B cells obtained 
from mIgG2b-HR or mIgG2b-LR to analyse, at the D N A  
level, whether hFc7 RIIa or another isoform of I1FC7 RII is 
responsible for the polymorphic binding o f mIgG2b. We have 
previously reported that EBV-transformed cells from 
mIgG2b-HR can provide, just like monocytes, accessory 
cell function in the mitogenic response to m !gG 2b anti- 
CD3 MoAb [9]. The presence on EBV-transformed cells of 
the polymorphic Fc receptor responsible for the binding of 
m!gG2b could be confirmed by EA-rosetting [9]. Whereas
monocytes express both I1FC7 RII and hFc7 RI (and some­
times also hFc7 RIII), EBV-transformed cells do not express 
hFc7 RI or I1FC7 RIII and therefore provide an excellent 
model to study the role of I1FC7 RII with respect to the 
mIgG2b. polymorphism. Furthermore, it was difficult to 
obtain sufficient numbers of highly purified monocytes or B 
cells from the few mIgG2b-HR available. We therefore 
decided to use only EBV-transformed B cells in the present 
study.
M A T E R IA L S  AND M E T H O D S
Cells. Leucocytes were obtained by cytapheresis from healthy 
donors, and peripheral blood mononuclear cells (PBMC) were 
isolated by centrifugation on Ficoll-Hypaque (Pharmacia Biotech, 
Uppsala, Sweden). Monocytes were purified from PBMC by coun­
terflow centrifugation [15] and were > 90% pure, as judged by 
staining with May-Grturwald-Giemsa and nonspecific esterase. 
They were cryopreserved [16] until use. We have demonstrated 
before that cryopreserved mononuclear cells or monocytes still dis­
play the mIgG2b polymorphism [9],
EBV-transformed B-cells were obtained from mIgG2b~HR or 
mIgG2b-LR individuals [9], and were cultured in RPMI-1640 
medium containing both Hepes and sodium bicarbonate (ICN 
Biomedicals, Costa Mesa, CA, USA), supplemented with 10% 
heat inactivated FCS (Hyclone, Logan, UT, USA), 2 him glutamine, 
ImM sodium pyruvate, 50/ig ml-1 streptomycin, and 50 IU mP1 
penicillin.
Oligonucleotides. All oligonucleotides were selected from the 
nucleotide sequences as published by Brooks et a l [13] (hFc7RIIbl: 
Genbank M31935; hFc7RIIa: Genbank M31932), and nucleotides 
are numbered according to this reference. With respect to hFc7RIIb,
Table 1. Oligonucleotides used for PCR analysis
Position Iso form-specific
Identification of iso forms:
P63 5'CAAGCCTCTGGTCAAGGTC nt 421-439 no
BECFII-3 5'CCACTACAGCAGCAACAATGGC nt 656-677 no
P52 5'GTCGTACCCGTCGAGAAG nt 631-648 yes
BEC-3int 5'CCACAGCCACAATGATCCCCAT nt 614-635 no
Sequencing extracellular part I1FC7RIIB:
BECFII-5 5'GCAGCTCCCCCAAAGGCT nt 83-100 no
BECFII-3 5 ; CCACTACAGCAGCAACAATGGC nt 656-677 no
BEC-5int 5'TCGAGCCCCAGTGGATCAAC nt 111-130 yes
BEC-3int 5'CCACAGCCACAATGATCCCCAT nt 614-635 no
Sequencing cytoplasmic part hFc7RIIB:
BCPII-5 S'ATTGTTGCTGCTGTAGTGGCC nt 659-679 no
BCPII-3 5 'AAACCTTCTCTTTTGGAACTG nt 981 - 1 0 0 1 y es
BCP-5int 5'GTAGTGGCCTTGATCTACTGC nt 671-691 no
Nucleotide (nt) numbers refer to I1FC7RIIB (numbered according to Brooke et a l [13]) 
except for P52, that is specific for I1FC7RIIA. Oligonucleotides BECFII-3, BECint, and BCPII-3 
are antisense and correspond to the reverse complement of the indicated nt sequences.
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several other groups [17-20] have published a virtually identical 
sequence with one exception: in contrast to Brooks et al. they all 
report the sequence G-C (not C-G) at nucleotide positions 980-981, 
and therefore we have assumed that this is the correct sequence at 
these positions.
The sequences for all oligonucleotides are given in Table L In 
order to identify the l1Fc7R.II isoform distribution of EBV-B cell 
lines, a partial sequence of hFc7R.II was amplified using two primers 
that do not distinguish between the different isoforms of I1FC7RII: 
P63 [21], that anneals in the extracellular region, and BECFII-3 
annealing in the transmembrane region. Subsequent hybridization of 
amplified DNA on Southern blots was then performed either with 
the hFc7RIIa-specific oligonucleotide probe P52 [21], or with BEC- 
3int that anneals to the extracellular part of all isoforms of hFc7RII.
F o r amplification of RNA coding for the complete extracellular 
p a r t  of I1FC7RII, we used a primer set consisting of BECFII-5 
annealing at the upstream end of the extracellular domain, and 
BECFII-3 (described above). These primers do not discriminate 
between the different isoforms of I1FC7RII. For subsequent sequen­
cing, two internal oligonucleotides were selected: BEC-5int, and 
BEC-3int (described above).
The cytoplasmic region of I1FC7RIIB was amplified using a sense 
primer BCPII-5 (annealing in the transmembrane region of 
I1FC7 RIIB), and an antisense primer BCPII-3 annealing in the 
untranslated part of the cytoplasmic region. For the sequencing of 
this comparatively short stretch of nucleotides, one internal oligo­
nucleotide was sufficient: BCP-5int (corresponding to a sequence in 
the transmembrane region of I1FC7RIIB).
All oligonucleotides were purified by reversed phase HPLC, 
Optimal annealing temperatures were empirically determined; ampli­
fication primer set BECFII-5/BECFII-3: 60°C; primer set BCPII-5/ 
BCPII-3: 52°C; primer set P63/BECFII-3: 56°C; all sequencing 
primers (BEC-5int, BEC-3int, and BCP-5int): 60°C; hybridization 
probe P52: 53°C; and hybridization probe BEC-3int: 63°C,
Oligonucleotides were radiolabelled by phosphorylation in a 20 p\ 
reaction volume containing 25-50pmoi oligonucleotide, 2 (A lOx 
kinase buffer (500 m u  Tris-HCl pH 7.5,100 mM MgCl2, 50 mM DTT, 
lm M  spermidine), 5—10/xl 32P-7ATP (3000 Ci/mmol, Amersham 
International, Amersham, UK) and 1 fA T4 polynucleotide kinase 
(10 U Pharmacia Biotech, Uppsala, Sweden) for 45 min at 37°C 
and  10 min at 68°C.
Labelled probes were purified by spin column centrifugation (G-25 
superfine DNA grade, Pharmacia Biotech, Uppsala, Sweden; 1 ml 
equilibrated in 0.1 x STE) using four elution volumes of 100^1 OJ x 
STE.
RNA isolation and PCR. Total cellular RNA was isolated from 
EBV-cells, monocytes, or cell lines U937, K562, Daudi and Raji, 
using the guanidine thiocyanate method [22], concentrated by etha­
nol precipitation, and stored at -70°C until use.
cDNA of the intended region was obtained by incubation of 1 fig 
total RNA for 10 min at 20°C, 45 min at 42°C and 10 min at 95°C in 
a reaction volume of 20 ¡A, containing 30pmol of the related down­
stream primer, 0.63 mM dNTP (Boehringer Mannheim, Mannheim, 
Germany), 10mM DTT, 20 U RNAsin (Promega, Madison, WI, 
USA), 4 (A 5x ‘first strand buffer’ (250mM Tris-HCl pH 8.3, 375 nw  
KCI, 15mM MgCl2) and 200 U M-MLV Reverse Transcriptase (Life 
Technologies Inc., Gaitersburg, MD, USA).
Subsequent amplification of acquired cDNA was performed in a 
thermal cycler (Perkin Elmer, Norwalk, CT, USA) after adding 80 (A 
o f  a PCR mixture, containing 30pmol upstream primer, 10¡A lOx
PCR buffer (500 mM KCI, 200mM Tris-HCl pH 8.4, 15mM MgCl2,
1 mg ml“ 1 BSA) and 1.5 U Taq polymerase (Life Technologies Inc., 
Gaitersburg, MD, USA) using an amplification protocol consisting 
of 5 min template denaturation at 94°C, 30 cycles for I min at 94°C, 1 
min at the primerset optimal annealing temperature and 1.5 min at 
72°C, followed by a terminal extension step for 10 min at 72°C.
For additional reamplification, 1 /A of PCR product was added to 
99 fA PCR mixture, containing 30pmol of each primer, 0.125mM 
dNTP, 10/il lOx PCR buffer, L5 U Taq polymerase and (when 
radiolabelled products were required) supplemented with P- 
adCTP (3000 Ci/mmol, Amersham International, Amersham, 
UK). Reamplification was performed using the amplification proto­
col described above.
Single strand conformation polymorphism. Radiolabelled PCR 
products diluted 1:5 in SSCP loading buffer (20mM EDTA pH 8.0,
20 mM NaOH, 0.05% xylene cyanol, 0.05% bromophenol blue in 
96% formamide) were heated for 3 min at 85°C and kept at 0°C for
10 min. Two fA treated samples were loaded on a polyacrylamide gel 
(6%, 49:1, optional 0-10% glycerol, in lx  TBE), separated at 
constant power (2 W) and gels were exposed to Kodak X-OMAT S 
film. In some experiments the PCR products were cleaved into two 
smaller fragments by adding 1 ¡A restriction enzyme Bgll (Life 
Technologies Inc., Gaitersburg, MD, USA) and 2 ¡A lOx reaction 
buffer (500 mM Tris-HCl pH 8.0, 100 mM MgCl2, 500 mM NaCl) and 
incubating for 60 min at 37°C.
Non-denaturating polyacrylamide gel electrophoresis. In order to 
separate the two hFc7 RIIB cytoplasmic region isoforms (bl and b2), 
5 i^l radiolabelled PCR products diluted 1:5 in TBE loading buffer 
(15% ficoll, 0.25% xylene cyanol, 0.25% bromophenol blue in lx  
TBE) were loaded on low-crosslinker polyacrylamidegel (6%, 49:1 in 
lx  TBE buffer). The gel was analysed by autoradiography and 
segments containing DNA bands of interest were cut out, dsDNA 
was extracted by adding 100 pi Tris-HCl pH 8.0, Imw EDTA 
incubating for 15 min at 80°C and 16 h at 4°C.
Hybridization analysis o f  PCR products. PCR products were 
analysed by separation on 2% (wt/vol) agarose and stained by 
ethidium bromide. Southern blotting was performed by transferring 
DNA to Hybond-N + (Amersham International, Amersham, UK) 
in 0.4m NaOH, 25mM EDTA. Membranes were washed (2x SSC) 
and incubated in 30 ml Standard Hybridisation mix [21] (5x SSC,
0.1% laurylsarcosine, 0.02% SDS 1% Blocking Reagent (Boehringer- 
Mannheim, Mannheim, Germany) for 1.5 h at the optimal annealing 
temperature. After adding 25pmol hybridization probe incubation 
was continued for 2 h at the same temperature followed by a washing 
procedure at stringency of 2x SSC, 0.1% SDS, twice at room 
temperature (20°C) and twice at the hybridization temperature. Blots 
were analysed after autoradiography using intensifying screens.
Sequence analysis. Prior to their use as templates in sequence 
analysis, PCR products were purified by the Wizzard PCR Preps 
DNA Purification System (Promega Corporation, Madison, WI, 
USA) according to the manufacturer’s description. They were then 
applied as template in the Sanger dideoxynucleotide termination 
sequencing method [23]. In brief, a 7.5¡A aliquot of a mixture, 
containing 10 ¡A purified template, 11 fA sequencing PCR buffer 
(30mM Tris-HCl pH 9.0, 5 him MgCl2, 30mM KCI, 0.025% NP-40,
0.025% Tween-20), 10^1 32P labelled sequencing oligonucleotide 
(2.5pmol in O.lx STE) and 0.5pi Taq polymerase (5 U fiV 1) was 
added to 2.5 pi of the four termination mixes individually containing 
160 fiM ddGTP, 80 ¡am dNTP; 1.28 mM ddATP, 40/¿m dNTP; 
1.92 him ddTTP, 40 /zm dNTP; 640 ¿am ddCTP, 40 ¿¿m dNTP ail
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diluted in sequencing PCR buffer and overlaid with 20 /¿I mineral oil. 
Sequencing reaction was performed according to the amplification 
protocol described above for 15 cycles. Reaction products were 
dispensed in 10 ¿¿I sequencing loading buffer (20 fxM EDTA pH 8,0,
0.05% xylene cyanol, 0.05% bromophenol blue, 91% formamide), 
heated for 4 min at 94°C before loading 3 ¡j\ on polyacrylamide gel 
(7%, optional 6 % , 24:1,7 m urea in 0.5x TBE). After separation and 
autoradiography the sequences were analysed*
R E SU L T S
hFc'yRIIB but not fiFc^RIIA  is present in EBV-transform ed B  
cells
RNA was isolated from EBV-transformed B cells of either 
mIgG2b-HR or mIgG2b-LR individuals, and R N A  coding 
for the extracellular part of hFc7 RII was amplified by RT- 
PCR using primers that do not discriminate between the 
different isoforms. The RT-PCR  products from the EBV- 
transformed cells hybridized with a probe recognizing both 
the hFc7 RIIA and hFc7 RIIB isoforms, bu t did no t hybridize 
with an hFc7 RIIA-specific probe (Fig. 1). Hybridization with 
the hFc7 RIIA-specific probe was observed with RT-PCR 
products obtained from monocytes, from cell lines U937 
and K562 and, very weakly, B cell line Daudi, and was not 
detectable with B cell line Raji. W e conclude that hFc7 RIIB 
but not hFc7 RIIA is present in the EBV-transformed cells 
(regardless whether they originate from m IgG 2b-H R  or LR 
individuals).
Single strand conformation polymorphism ( SSC P ) analysis o f  
hFc^RIJB
We then focused on a more detailed analysis of I1FC7 RIIB 
obtained from the EBV-transformed cells, and investigated 
whether there was a polymorphism detectable at the DNA 
level. Our first approach was SSCP analysis, which may 
detect allelic forms of DNA. We found no indications for 
allelism o f I1FC7 RIIB, not even when (after cleavage by 
restriction enzymes) shorter stretches o f D N A  were analysed.
Sequencing o f  hFc^RIJB
Since SSCP analysis can reveal allelic differences but the 
absence of detectable differences is not conclusive, we decided 
to sequence the extracellular part o f hFc7 RIIB. As shown in 
Table 2 , this sequence was completely identical for mIgG2b- 
H R  and m!gG2b-LR individuals. The same sequence was 
found in a total of four high-responders and three low- 
responders.
Whereas the extracellular part of the receptor is responsible 
for ligand binding, the cytoplasmic tail is involved in signal 
transduction (as discussed below), and therefore it was con­
ceivable that a difference in the sequence of the intracellular 
part of the receptor would affect its biological effects, There­
fore we also sequenced the intracellular part of I1FC7 RIIB. 
We found that both the hFc7 R IIb l and the hFc7RIIb2 
isoform were present (bl containing a 57-nucleotide insert 
when compared with b2). Again, we found no sequence 
differences when RT-PCR products from four mIgG2b-HR 
and three m!gG2b-LR were analysed (data not shown).
D IS C U S S IO N
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Fig. 1. Expression of hFc7RIIb but not hFc7RIIa in EBV- 
transformed B cells. RNA coding for the extracellular part of 
I1FC7RII was amplified by RT-PCR using a primer set that does 
not discriminate between hFc7RIIa or hFc7RIIb. After Southern 
blotting, hybridization was performed with a probe specific for 
hFc7RIIa (panel a), or a probe that recognizes both hFc7RIIa and 
hFc7RIIb (panel b). Lane 1: no DNA. Lanes 2-5: cell lines U937, 
K562, Daudi, and Raji, respectively. Lane 6: monocytes of 
mIgG2b high-responder. Lanes 7-9: EBV-transformed cells from 
three mIgG2b high-responders. Lanes 10-12: EBV-transformed 
cells from three m!gG2b low-responders.
We have previously reported that mIgG2b can bind in a 
polymorphic way to human mononuclear cells. The presence 
of an Fc receptor that can interact with mIgG2b could also be 
demonstrated on EBV-transformed cells from mIgG2b-HR 
[9]. These EBV-transformed cells had the phenotype of B 
cells, and they did not express I1FC7 RI or I1FC7 RIIL In 
immunofluorescence studies, staining was seen with MoAb 
KB61 but not M oAb IV.3 [9]. KB61 recognizes the hFc7RIIb 
isoform present on B cells, whereas IV.3 primarily binds to 
hFc7 R IIa that is expressed on monocytes and granulocytes 
[24].
An isoform of I1FC7 RII is responsible for the polymorphic 
binding of m lg G l, and it has been suggested that I1FC7 RII is 
responsible for binding of m IgG2b [12]. In functional studies, 
however, we found no evidence for an involvement of 
I1FC7 RII in the polymorphic binding o f mIgG2b. MoAbs 
against I1FC7 R II (including KB61) did not inhibit mIgG2b 
anti-CD3 induced T cell proliferation [9]. Furthermore, pro­
teolytic enzymes strongly reduced the expression of hFc7 RII 
on EBV-transformed cells, whereas they caused an increased 
binding of mIgG2b in EA-rosetting [11]. Although these 
findings argue against the hypothesis that the polymorphic
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Table 2. Sequence of extracellular part of hRrpRIIb in mIgG2b high-responder/low- 
responder EBV B-cell lines
HR CTCCAGGAGG ACTCTGTGAC TCTGACATGC CGGGGGACTC ACAGCCCTGA GAGCGACTCC
* * * * * * * * * * ^  ^  ^  ^  Wa ^Lf L^p*  ^  ^  ^  ^  ^  ^  ^  ^ * * * * * * * * * * * * * * * * * * * * ■Jj— i^ L« «la ^  ^  ^ P  ^  r f i  ^  ^  ^  ^
LR CTCCAGGAGG ACTCTGTGAC TCTGACATGC CGGGGGACTC ACAGCCCTGA GAGCGACTCC
HR ATTCAGTGGT TCCACAATGG GAATCTCATT CCCACCCACA CGCAGCCCAG CTACAGGTTC
* *  * *  *  *  *  sfeo tc  * ^  ^  ^  iI j  ^  ^  ^  ^  ^  ^  ^ %  *  %  *  * *  %  *  *  * A f^ ^  «V ^  ^  ^  ^
LR ATTCAGTGGT TCCACAATGG GAATCTCATT CCCACCCACA CGCAGCCCAG CTACAGGTTC
HR AAGGCCAACA ACAATGACAG CGGGGAGTAC ACGTGCCAGA CTGGCCAGAC CAGCCTCAGC
iXr w  W  «4# U* ^  ^  J a  ^  «L ^
^  ^  ^  ^  ^  ^  ^  ^  ^
^  ^  ^  >|1^ sT  ~J~* w  xU  ^  iM  i f ' mfiv ^  %L Lip t¿A ^  
^  ^  ^  ^  ^  ^  ^
LR AAGGCCAACA ACAATGACAG CGGGGAGTAC ACGTGCCAGA CTGGCCAGAC CAGCCTCAGC
HR GACCCTGTGC ATCTGACTGT GCTTTCTGAG TGGCTGGTGC TCCAGACCCC TCACCTGGAG
|X» U j Uj
*  * * * * *  *  *  * * ^p ^ ^  ^  ^  tjrf ^  ^  mjj- ^  ^p  ^p  ^p U# ^  U|/ ^  «it-- ^  rnL. U j  ^ ^  ^  ^  ^  ^  ^  ^ U j
LR GACCCTGTGC ATCTGACTGT GCTTTCTGAG TGGCTGGTGC TCCAGACCCC TCACCTGGAG
HR TTCCAGGAGG GAGAAACCAT CGTGCTGAGG TGCCACAGCT GGAAGGACAA GCCTCTGGTC
iJfl u #  t l j  kIa
* * * * * * * * * *
^  ^  |¿» ^  hL ^  «X*
"T*
^^ 4 1^# 
^  ^  ^  ^  ^  ^  ^
^  ^  Xl¿ «X» ¿ é
^p ^p  ^ p  ^p
« l i  n¿» à|# ^  ^  ^  %U 
^  ^  ^  ^  ^  ^  ^  ^
LR TTCCAGGAGG GAGAAACCAT CGTGCTGAGG TGCCACAGCT GGAAGGACAA GCCTCTGGTC
HR AAGGTCACAT TCTTCCAGAA TGGAAAATCC AAGAAATTTT CCCGTTCGGA TCCCAACTTC
* * * * * * * * * * ^  ^  ^  ^  3 p  ^  ^ i¿P ü p  lIj  ^  bjji+r* ^  Vti ^  1¿É kL ^  ^ ^  ^  ^  Vp ^ ^  ^  r p  ^ ^  ^
LR AAGGTCACAT TCTTCCAGAA TGGAAAATCC AAGAAATTTT CCCGTTCGGA TCCCAACTTC
HR TCCATCCCAC AAGCAAACCA CAGTCACAGT GGTGATTACC ACTGCACAGG AAACATAGGC
^  ^  J j  «L  d i  U j  ^  
^  ' p  ^  ^  ^  ^  ^
^  klj ^  ^  
^  A  ^  ^  A  / p  ^  m
||Ja u j  iU
T’  ^m*
fcL« hL « L  ü *  U i  u j  ^  ^  
^  ^  ^  ^  ^
^  ^  4 L  ^  ^  *1» J lj ^  
Fpp ^  ^  ^  ^  ^  ^  ^
«JU «X» ^  t j f t  ^  ^
LR TCCATCCCAC AAGCAAACCA CAGTCACAGT GGTGATTACC ACTGCACAGG AAACATAGGC
HR TACACGCTGT ACTCATCCAA GCCTGTGACC ATCACTGTCC AAGCTCCCAG CTCTT
^  ^  ^  
^  ^  ^  r p  ^  ^  ^  ^  ^ * * * * * * * * * * -jj- «L ^  ^  ^  ^  ’T' ■JL|B aXp tip u j  ^L* l u  ^ lj u >  ^  ^  ^  ^  ^  ^  ^ ^ p  ^ p  ^
LR TACACGCTGT ACTCATCCAA GCCTGTGACC ATCACTGTCC AAGCTCCCAG CTCTT
Nucleotide sequence of the extracellular part of hFc7RIIb in EBV-transformed B cells is 
identical formIgC2b high-responders and low-responders. After amplification by RT-PCR, 
sequencing was carried out by the Sanger method. The same sequence was found in a total of 
four mIgG2b-HR and three m!gG2b-LR.
binding of mIgG2b is caused by a polymorphic isoform of isoforms at R N A  level. Sartnay et al. have studied isoform
h F c 7RII, we felt that only an analysis at the D N A  level (by 
sequencing) could yield definitive conclusions. Furthermore,
expression in resting and activated B cells. In resting B cells, 
hFc7 R IIb2 was the predom inant isoform, although
b y  performing RT-PCR with primers that correspond to hFc7 R IIb l and (at a  low level) hFc7 R IIa were also present,
conserved sequences present in all identified isoforms of U pon activation the expression o f  hFc7 RIIbl increased,
h F c7 RII> there was the possibility that we might identify whereas hFc7 R IIb2 and hF c7 R IIa decreased [25]. As we
another very homologous but polymorphic isoform of reported before, the EBV-transformed cells have a high
h F c 7 RII in the EBV-transformed cells. expression of H L A -D R  and transferrin receptor, and in this
Our hybridization and sequencing experiments revealed respect they resemble activated rather than resting B cells [11].
th a t  transcripts encoding for hFc7RIIbl and hFc7 R IIb2 , W ith respect to I1FC7 RIIA, we found abundant expression in
b u t not for hFc7RIIa are present in EBV-transformed B monocytes and the cell lines U937 and K562. B cell line Daudi
cells. The absence of an hFc7RIIa transcript is consistent expressed I1FC7 R IIA  at a very low level, but in B cell line Raji
w ith the absence of immunofluorescence staining with MoAb it was not detectable* These results with cell lines are very
IV.3, that primarily recognizes this isoform [9]. To our similar to results obtained after Northern analysis [13], 
knowledge EBV-transformed cells have not been analysed although others have reported expression of I1FC7 RIIA in 
before with respect to the expression of different hFc7 RII several B cell lines including Raji [25, 26].
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We could not detect allelic differences in hFc^RIIB  
between mIgG2b-HR and m IgG 2b-LR by the SSCP analysis. 
To ascertain that there are indeed no differences in sequence, 
we determined the nucleotide sequence in a total of seven 
EBV-transformed cell lines. The sequence for the extracellu­
lar part (Table 2) is exactly the same as reported by Brooks et 
al. [13], except for an A instead o f a T  at position 564. Two 
other groups have also reported an A  at the corresponding 
position [19, 20]. More importantly, the same nucleotide was 
found in both m IgG2b-HR and mIgG2b-LR. Since the 
primers used for sequencing the extracellular part o f the 
receptor do not discriminate between hFcvRIIb and 
hFc7 RIIc, it is obvious that even in the case that hFc7 RIIc 
would be expressed in these cells the nucleotide sequence 
would be identical for m IgG 2b-H R  and m IgG 2b-LR.
Finally, we sequenced the intracellular region of 
hFc7 RIIB. Studies on the corresponding murine Fc receptor 
have revealed that the cytoplasmic domain of the receptor 
determines its ability to endocytose immune complexes [27]. 
Similarly, the association of different isoforms of hFc7 RIIb 
with intracellular molecules and their biological function is 
determined by the cytoplasmic dom ain [28]. It was therefore 
conceivable that differences in EA-rosetting between H R  and 
LR were caused by differences in the intracellular part of 
hFc7 RIIb. We found that both hFc7 R IIb l and hFc7 RIIb2 
were present in the EBV-transformed cells, but there were no 
differences in sequence between m IgG 2b-H R  and mIgG2b- 
LR. The sequence we found was precisely the same as 
reported by Brooks et al. [13],
Identity of the nucleotide sequences predicts that the poly­
peptide chain of hFc7 R IIb is identical for m IgG 2b-H R and 
mIgG2b-LR. Our data cannot exclude the possibility that a 
difference in glycoprotein structure exists as a result of 
differences in glycosylation, although there are no experi­
mental data to support this possibility.
Recently, a polymorphism of the I1FC7 R IIIA  gene was 
identified [29]. Although in immunofluorescence experiments 
no evidence was found for expression of this receptor on 
EBV-transformed cells [9], mononuclear cells from five 
mIgG2b~HR were genotyped for this I1FC7 R IIIA  polymorph­
ism. However, no association with a particular I1FC7 RIIIA  
allele was found (M. de Haas, personal communication).
In conclusion, we found that bo th  hFc7R IIb l and 
hFc7 R IIb2 but not hFc7 R IIa are detectable in EBV-trans- 
formed B cells that bind mIgG2b. The hFc7 R IIb  isoforms do 
not display any sequence difference between m IgG2b-HR 
and mIgG2b-LR cells. Therefore we conclude that the poly­
morphic binding of mIgG2b to hum an B cells cannot be 
ascribed to one of the iso forms o f I1FC7 RIL This conclusion is 
also supported by our previous studies on the effect of 
proteolytic enzymes on Fc receptor expression and function 
[11], Furthermore, since there is no evidence that I1FC7 R I or 
I1FC7 R III can be expressed on EBV-transformed B cells [9], 
we must conclude that apparently a yet unidentified I1FC7 R 
different from hFc7 RI, hFc7 R II, or I1FC7 RIII is responsible
for the polymorphic binding of mIgG2b to B cells. Although 
we did not perform a similar analysis with monocytes, it 
should be stressed that accessory cell function in mIgG2b 
anti-CD3 induced T  cell proliferation can be provided by 
EBV-transformed B cells from mIgG2b-HR as adequately as 
by H R  monocytes [9]. A  recent study on the effects of human 
IgG2 on human B cells also concluded that these effects were 
mediated by a I1FC7 R  different from the three receptors 
identified so far [30].
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